CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

drug protocol number
8535C00001
drug sponsor
Astrazeneca
drug study
Camizestrant (AZD9833)
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Ongoing
drug phase